GENFIT Expands NASHnext® Access via Labcorp OnDemand for At-Risk MASH Detection — GENFIT S.A.

Event summary

GENFIT’s NASHnext® test, powered by NIS4® technology, is now available through Labcorp’s OnDemand platform, enabling broader access for at-risk MASH identification.
The test addresses diagnostic gaps in routine care, offering a non-invasive alternative to liver biopsies and costly imaging.
Labcorp OnDemand allows patients to order the test online, with results reviewed by healthcare professionals.
GENFIT estimates a U.S. patient population in the high tens of millions could benefit from NASHnext® testing.

The big picture

GENFIT’s partnership with Labcorp OnDemand underscores the growing need for scalable, non-invasive diagnostic tools in the MASH space. As therapeutic options for MASH expand, the ability to identify at-risk patients earlier could drive significant market shifts. The test’s availability through Labcorp OnDemand positions GENFIT to capitalize on the high prevalence of metabolic risk factors in the U.S., potentially influencing future diagnostic and treatment paradigms.

What we're watching

Reimbursement Dynamics: Whether Medicare/Medicaid will approve reimbursement for NASHnext®, which would significantly expand its accessibility.
Market Adoption: The pace at which NASHnext® is adopted in primary care and endocrinology settings, given its non-invasive nature.
Strategic Partnerships: How GENFIT’s potential collaborations with pharmaceutical companies will impact the broader deployment of non-invasive MASH testing.